Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 20/20 | 0.75 |
| ▸ | HDAC3 | O15379 | 19/20 | 0.75 |
| ▸ | HDAC4 | P56524 | 19/20 | 0.75 |
| ▸ | HDAC7 | Q8WUI4 | 19/20 | 0.75 |
| ▸ | HDAC2 | Q92769 | 19/20 | 0.75 |
| ▸ | HDAC10 | Q969S8 | 19/20 | 0.75 |
| ▸ | HDAC11 | Q96DB2 | 19/20 | 0.75 |
| ▸ | HDAC8 | Q9BY41 | 19/20 | 0.75 |
| ▸ | HDAC6 | Q9UBN7 | 19/20 | 0.75 |
| ▸ | HDAC9 | Q9UKV0 | 19/20 | 0.75 |
| ▸ | HDAC5 | Q9UQL6 | 19/20 | 0.75 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1482193 | 1.00 | HDAC1 (0.75) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL1481392 | 0.92 | HDAC1 (0.71) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL1481395 | 0.92 | HDAC1 (0.71) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL1481775 | 0.91 | HDAC3 (0.61) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL1481781 | 0.91 | HDAC3 (0.61) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL2326243 | 0.87 | HDAC3 (0.75) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL2324621 | 0.87 | HDAC3 (0.75) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL2326721 | 0.86 | HDAC1 (0.74) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL2326725 | 0.86 | HDAC1 (0.74) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL1481949 | 0.86 | HDAC3 (0.81) | HDAC1HDAC3HDAC4HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242175-B2 | Class of histone deacetylase inhibitors | DAC S.R.L. (IT) | 2012-08-14 | — | — | US | claimed |
| US-20110077247-A1 | CLASS OF HISTONE DEACETYLASE INHIBITORS | DAC S.r.I. (IT) | 2011-03-31 | — | — | US | claimed |
| EP-2049508-B1 | N-HYDROXY-3-(4-{3-PHENYL-3-OXO-PROPENYL}-PHENYL)-ACRYLAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER | DAC SRL (IT) | 2010-06-09 | — | — | EP | claimed |
| US-20100113438-A1 | CLASS OF HISTONE DEACETYLASE INHIBITORS | DAC S.R.L. (IT) | 2010-05-06 | — | — | US | claimed |
| EP-2049508-A2 | N-HYDROXY-3-(4-{3-PHENYL-3-OXO-PROPENYL}-PHENYL)-ACRYLAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER | DAC S.r.l. (IT) | 2009-04-22 | — | — | EP | claimed |
| WO-2007113249-A2 | N-HYDROXY-3-(4-{3-PHENYL-S-OXO-PROPENYL}-PHENYL)-ACRYLAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER | DAC S.R.L. (IT) | 2007-10-11 | — | — | WO | claimed |
| US-8242175-B2 | Class of histone deacetylase inhibitors | DAC S.R.L. (IT) | 2012-08-14 | — | — | US | disclosed |
| US-20110077247-A1 | CLASS OF HISTONE DEACETYLASE INHIBITORS | DAC S.r.I. (IT) | 2011-03-31 | — | — | US | disclosed |
| EP-2049508-B1 | N-HYDROXY-3-(4-{3-PHENYL-3-OXO-PROPENYL}-PHENYL)-ACRYLAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER | DAC SRL (IT) | 2010-06-09 | — | — | EP | disclosed |
| US-20100113438-A1 | CLASS OF HISTONE DEACETYLASE INHIBITORS | DAC S.R.L. (IT) | 2010-05-06 | — | — | US | disclosed |
| EP-2049508-A2 | N-HYDROXY-3-(4-{3-PHENYL-3-OXO-PROPENYL}-PHENYL)-ACRYLAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER | DAC S.r.l. (IT) | 2009-04-22 | — | — | EP | disclosed |
| WO-2007113249-A2 | N-HYDROXY-3-(4-{3-PHENYL-S-OXO-PROPENYL}-PHENYL)-ACRYLAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER | DAC S.R.L. (IT) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077247-A1 | CLASS OF HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC11 | HDAC1 2/4885HDAC3 1/4885HDAC4 5/4885 |
| US-20100113438-A1 | CLASS OF HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC11 | HDAC1 2/4885HDAC3 1/4885HDAC4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.